Average Co-Inventor Count = 6.95
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Novartis Ag (41 from 3,923 patents)
2. Speedel Experimenta Ag (4 from 5 patents)
3. Ciba-geigy Corporation (1 from 6,850 patents)
4. Novartis Corporation (1 from 166 patents)
5. Novartis Pharma Ag (1 from 29 patents)
48 patents:
1. 11702409 - Pyrazolyl derivatives useful as anti-cancer agents
2. 10786492 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors
3. 10507201 - Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
4. 10189813 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors
5. 10130629 - Pharmaceutical combinations
6. 9896449 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
7. 9802917 - Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
8. 9556180 - Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
9. 9533988 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
10. 9403827 - Substituted purinone compounds
11. 9365576 - Pyrrolopyrrolidinone compounds
12. 9266883 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
13. 8969341 - Pyrazolopyrrolidine compounds
14. 8815926 - Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
15. 8680079 - Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors